CV-301
A cancer immunotherapy product candidate incorporating two
antigens (CEA and MUC-1) that are overexpressed in other major
cancers, including breast, lung, and ovarian.
Company
Announcement
5 October 2011
Bavarian Nordic Obtains Rights to New Cancer Vaccine Product
Candidates
English
version
Danish
version
Additional
information
Fact sheet
Scientific
Publications
Presentation
Download presentation from the
conference call:
Presentation
Conference Call
A conference call was held on 5 October
2011 at 6 p.m. CET (12 p.m. EST) with Anders Hedegaard, President
& CEO, Reiner Laus, CEO of BN ImmunoTherapeutics Inc. and Rolf
Sass Sørensen, Vice President Investor Relations &
Communications.
Transcript
Listen to the replay:
